Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 3 of the 18 sources its claims cite were checked for support.
Abstract
BACKGROUND: An intranasal formulation of esketamine, combined with an oral antidepressant, is approved in the USA and the European Union for adults with treatment-resistant depression (TRD). Transient cardiovascular stimulatory effects have been reported with ketamine. METHODS: Cardiovascular effects of esketamine nasal spray, combined with an oral antidepressant, were evaluated in 1708 esketamine-treated adults with TRD in six trials (five double-blind, placebo-controlled (486 placebo-treated patients); one open-label) of 4-52 weeks' duration. Patients with established cardiovascular disease, including uncontrolled hypertension (> 140/> 90 mmHg), history of hypertensive crisis, or clinically significant electrocardiogram (ECG) abnormalities, were excluded from enrollment. Effects on cardiac repolarization were assessed in a phase I randomized, positive- and active-controlled thorough corrected QT (QTc) interval study. For adverse events, odds ratio (OR) [95% confidence interval] for esketamine/antidepressant versus antidepressant/placebo was calculated. RESULTS: Adverse events related to increased BP were reported in 12.8% of all esketamine-treated patients (in double-blind trials: esketamine/antidepressant 11.6% vs. antidepressant/placebo 3.9%; OR 3.2 [1.9-5.8]). Among the patients without a history of hypertension, new antihypertensive medication was initiated by 2.1% (6/280) of patients in the esketamine/antidepressant group versus 1.2% (2/171) of patients in the antidepressant/placebo group, in the double-blinded studies. Adverse events related to abnormal heart rate were reported in 3.0% of all esketamine-treated patients (in double-blind trials: 1.6% vs. 0.8%; OR 1.9 [0.5-8.6]). Overall, three cardiovascular adverse events related to BP increase were reported as serious and severe, and there was one fatal event considered unrelated (acute cardiac failure). BP increases reached the maximum postdose value within ~ 40 min of esketamine dosing and returned to the predose range by ~ 1.5 h postdose. In two studies (4-week duration, age 18-64 years), the largest mean maximum systolic/diastolic postdose BP increases were 13.3/8.7 mmHg for esketamine/antidepressant and 6.1/4.9 mmHg for antidepressant/placebo, and in a short-term elderly study (age ≥ 65 years) were 16.0/9.5 and 11.1/6.8 mmHg, respectively. Across studies/study phases, < 2% of patients discontinued esketamine due to adverse events of increased BP and tachycardia. No clinically relevant effect on ECG parameters was observed. Therapeutic and supratherapeutic doses of esketamine did not prolong the QTcF (QT corrected by Fridericia's equation) interval (baseline-corrected values of - 2.02 to 2.16 ms, and - 3.51 to 4.89 ms, respectively). CONCLUSIONS: BP elevations following esketamine dosing are generally transient, asymptomatic, and not associated with serious cardiovascular safety sequalae. Further evaluation of long-term cardiovascular outcomes is warranted.
Overview
CoChat Summary
TL;DR
In six trials of esketamine nasal spray plus an oral antidepressant in treatment-resistant depression (1708 esketamine-treated, 486 placebo-treated), blood pressure increases were common but generally transient, asymptomatic, and not linked to serious cardiovascular sequelae. No clinically relevant effect on ECG parameters or QTcF was observed, though long-term cardiovascular outcomes remain unknown.
Key findings
- Increased BP-related adverse events occurred in 12.8% of all esketamine-treated patients; in double-blind trials, 11.6% with esketamine/antidepressant vs 3.9% with antidepressant/placebo (OR 3.2 [95% CI 1.9–5.8]). Most were mild or moderate (98%) and resolved (94%).
- Abnormal heart rate-related adverse events occurred in 3.0% of all esketamine-treated patients; in double-blind trials, 1.6% vs 0.8% (OR 1.9 [95% CI 0.5–8.6]), with 96% mild/moderate and 88% resolved.
- BP increases peaked within ~40 min of dosing and returned to predose range by ~1.5 h. Largest mean maximum SBP/DBP increases were 13.3/8.7 mmHg for esketamine/antidepressant vs 6.1/4.9 mmHg for antidepressant/placebo in 18–64-year-olds, and 16.0/9.5 vs 11.1/6.8 mmHg in elderly patients. Discontinuation due to increased BP and tachycardia was <2% across studies/phases.
- Therapeutic and supratherapeutic esketamine did not prolong QTcF: baseline-corrected values ranged from −2.02 to 2.16 ms and −3.51 to 4.89 ms, respectively, below the 10 ms ICH E14 threshold. Three serious and severe BP-related cardiovascular adverse events were reported in two patients; one fatal event of acute cardiac failure was considered unrelated.
Methods
- Pooled cardiovascular safety analysis from five double-blind, placebo-controlled phase II/III studies and one open-label phase III study of esketamine nasal spray plus oral antidepressant in adults with TRD; 1708 esketamine-treated and 486 placebo-treated patients, 4–52 weeks’ duration. Patients with established cardiovascular disease, uncontrolled hypertension (>140/>90 mmHg), history of hypertensive crisis, or clinically significant ECG abnormalities were excluded.
- Assessments included adverse events, vital signs, and ECG monitoring; BP and pulse/heart rate were measured at baseline and dosing visits. A phase I randomized, positive- and active-controlled thorough QTc study used oral moxifloxacin 400 mg as positive control and esketamine 84 mg nasal spray and 0.8 mg/kg IV infusion.
- For adverse events, odds ratios with two-sided exact 95% CIs were calculated for esketamine/antidepressant vs antidepressant/placebo in the All Randomized, Blinded Trials TRD Population; other analyses were descriptive.
Limitations
- Stated: generalizability may be limited by exclusion of patients with cardiovascular disease within 12 months before trial start, uncontrolled hypertension at enrollment, or clinically significant ECG abnormalities; BP elevations or ECG changes between dosing sessions were not routinely documented; long-term effects of repeated transient BP increases lasting 1–4 h are unknown, and further long-term cardiovascular outcome monitoring is warranted.
- Evident from the text: the safety analyses are largely descriptive outside the double-blind adverse-event odds ratios, and the long-term open-label study contributes substantial exposure data without a parallel control group, limiting causal inference for rare or long-term cardiovascular events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Mean [± standard error (SE)] blood pressure over time from the induction phase of 4-week double-blind studies of patients with treatment-resistant depression (TRD) aged 18–64 years [5, 6]](https://figures.cochat.ai/paper-figures/03b62f0d8f3942a29c691daa8594e20c/cardiac-safety-of-esketamine-nasal-spray-in-treatment-resistant-depression-figure-1.jpg)
![Fig. 2 Mean maximum [± standard error (SE)] and maximum change in postdose blood pressure: pooled results from the induction phase of 4-week double-blind studies of patients with treatment-resistant depression (TRD) aged 18–64 years [5, 6]](https://figures.cochat.ai/paper-figures/2121434d217f4e3594240f85e6ae88e1/cardiac-safety-of-esketamine-nasal-spray-in-treatment-resistant-depression-figure-2.jpg)
Verification
Claims the paper makes
1 Valid · 0 Not valid · 13 Not checked · 59 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the phase I thorough QTc study, the mean difference (90% CI) from placebo for change in baseline-corrected QTcF over the 30-h postdose interval ranged from − 2.02 ms (− 4.173 to 0.137) to 2.16 ms (0.018 to 4.310) for the 84 mg intranasal esketamine dose and from − 3.51 ms (− 5.721 to − 1.294) to 4.89 ms (2.676 to 7.102) for the 0.8 mg/kg IV infusion (data on file).”
§ Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 16.0/9.5 and 11.1/6.8 mmHg, respectively, in the elderly study (TRANSFORM-3).”
§ Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therapeutic and supratherapeutic doses of esketamine did not prolong the QTcF (QT corrected by Fridericia’s equation) interval (baseline-corrected values of − 2.02 to 2.16 ms, and − 3.51 to 4.89 ms, respectively).”
§ Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In two studies (4-week duration, age 18–64 years), the largest mean maximum systolic/diastolic postdose BP increases were 13.3/8.7 mmHg for esketamine/antidepressant and 6.1/4.9 mmHg for antidepressant/placebo”
§ Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and in the long-term open-label safety study, 2.4% (eight of 330 events).”
§ Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
42 more claims
Create a free account to see all 73 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 20
- The quote only partly states this claim. 1
Citations
Cites
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationInternational Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Miller, R. D. (2005) · Cited by 1,241
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
van Melle, J. P., de Jonge, P., Spijkerman, T. A., Tijssen, J. G. P., Ormel, J., van Veldhuisen, D. J., van den Brink, R. H. S., & van den Berg, M. P. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000146294.82810.9c · Cited by 1,034
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Self-citationDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Self-citationDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Self-citationFedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Self-citationKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510703 · Cited by 134
Long-term safety of ketamine and esketamine in treatment of depression
Nikayin, S., Murphy, E., Krystal, J. H., & Wilkinson, S. T. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2066651 · Cited by 120
“only one patient had an increased QTc over 500 ms [52].”
BackgroundDepression: Biological markers and treatment
Erjavec, G. N., Šagud, M., Perković, M. N., Štrac, D. Š., Konjevod, M., Tudor, L., Uzun, S., & Pivac, N. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110139 · Cited by 136
Ceban, F., Rosenblat, J. D., Kratiuk, K., Lee, Y. L., Rodrigues, N. B., Gill, H., Subramaniapillai, M., Nasri, F., Lui, L. M. W., Lipsitz, O., et al. (2021) · CNS Drugs · doi:10.1007/s40263-021-00846-5 · Cited by 102
“Parenthetically, esketamine may necessitate antihypertensive treatment less frequently than ketamine [47].”
Background
Metadata
- Authors
- Doherty, T., Wajs, E., Melkote, R., Miller, J., Singh, J. B., & Weber, M. A.
- Affiliations
- Janssen Research & Development (United States) (US)
- Janssen (Belgium) (BE)
- Neurocrine Biosciences (United States) (US)
- SUNY Downstate Health Sciences University (US)
- Corresponding author
- Doherty, Teodora
- Venue
- CNS Drugs
- Published
- 2020-01-29
- Volume
- 34
- Issue
- 3
- Pages
- 299-310
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC7048867
- OpenAlex
- W3004365315
- Cited by
- 68
- References
- 20
- Citations by year
- 2026: 14 · 2025: 8 · 2024: 3 · 2023: 8 · 2022: 13 · 2021: 12 · 2020: 9
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Janssen Research and Development, LLC, Titusville, NJ, USA
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Keywords
- esketamine nasal spray, treatment-resistant depression, cardiovascular safety, blood pressure increase, heart rate increase, QTc interval, cardiac repolarization, hypertension, adverse events, antidepressant combination therapy, ketamine
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Aged, Aged, 80 and over, Antidepressive Agents, Double-Blind Method, Female, Heart, Humans, Ketamine, Male, Middle Aged, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Young Adult, Nasal Sprays, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program. https://app.cochat.ai/papers/10.1007/s40263-020-00699-4
- The paper
- Doherty, T., Wajs, E., Melkote, R., Miller, J., Singh, J. B., & Weber, M. A. (2020). Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program. CNS Drugs. https://doi.org/10.1007/s40263-020-00699-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.